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Abstract	Dysregulation	of	signaling	pathways	in	Multiple	Sclerosis	(MS)	can	be	analyzed	by	phosphoproteomics	 in	 peripheral	 blood	 mononuclear	 cells	 (PBMCs).	 We	performed	 in	 vitro	kinetic	 assays	on	PBMCs	 in	195	MS	patients	 and	60	matched	controls	 and	 quantified	 the	 phosphorylation	 of	 17	 kinases	 using	 xMAP	 assays.	Phosphoprotein	 levels	were	 tested	 for	 association	with	 genetic	 susceptibility	 by	typing	 112	 single-nucleotide	 polymorphisms	 (SNPs)	 associated	 with	 MS	susceptibility.	 We	 found	 increased	 phosphorylation	 of	 MP2K1	 in	 MS	 patients	relative	 to	 the	 controls.	Moreover,	 we	 identified	 one	 SNP	 located	 in	 the	 PHDGH	gene	and	another	on	IRF8	gene	that	were	associated	with	MP2K1	phosphorylation	levels,	 providing	 a	 first	 clue	 on	 how	 this	MS	 risk	 gene	may	 act.	 The	 analyses	 in	patients	 treated	 with	 disease	modifying	 drugs	 identified	 the	 phosphorylation	 of	each	receptor’s	downstream	kinases.	Finally,	using	flow	cytometry,	we	detected	in	MS	patients	increased	STAT1,	STAT3,	TF65	and	HSPB1	phosphorylation	in	CD19+	cells.	 These	 findings	 indicate	 the	 activation	 of	 cell	 survival	 and	 proliferation	(MAPK),	 and	 pro-inflammatory	 (STAT)	 pathways	 in	 the	 immune	 cells	 of	 MS	patients,	primarily	in	B	cells.	The	changes	in	the	activation	of	these	kinases	suggest	that	 these	pathways	may	represent	 therapeutic	 targets	 for	modulation	by	kinase	inhibitors.		
Keywords:	 multiple	 sclerosis,	 autoimmunity,	 immunomodulatory	 drugs,	phosphoproteomics,	genetic	susceptibility,	signaling	pathways,	kinases,	B	cells.	
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Significance	statement		The	 alteration	 of	 cell	 communication	 in	 the	 immune	 system	 of	 patients	 with	Multiple	 Sclerosis	 (MS)	 can	 be	 analyzed	 by	 phosphoproteomics	 in	 immune	 cells.	We	performed	in	vitro	assays	on	immune	cells	from	MS	patients	and	controls	and	quantified	 the	 phosphorylation	 of	 several	 kinases.	 We	 found	 increased	phosphorylation	 of	 several	MAPK	 kinases	 in	 patients,	which	were	modulated	 by	several	genetic	markers	associated	with	the	disease.	By	using	flow	cytometry,	we	detected	 altered	 phosphorylation	 of	 several	 kinases	 in	 B	 cells.	 These	 findings	indicate	 the	 activation	 of	 cell	 survival	 and	 proliferation	 (MAPK),	 and	 pro-inflammatory	(STAT)	pathways	in	the	immune	cells	of	MS	patients,	primarily	in	B	cells.	The	changes	 in	 the	activation	of	 these	kinases	 suggest	 that	 these	pathways	may	represent	therapeutic	targets	for	modulation	by	kinase	inhibitors.	
 	
5	
 
\body	
Introduction	Analyzing	signaling	pathways	in	patients	with	Multiple	Sclerosis	(MS)	may	provide	insights	 into	 processes	 likely	 to	 drive	 the	 immune	 cell’s	 response,	 as	 well	 as	 to	influence	the	effects	of	drugs1.	Phosphoproteomic	analyses	provide	opportunities	to	 evaluate	 the	 activation	 of	 signaling	 cascades,	 and	 such	 studies	 may	 help	 to	identify	the	pathways	activated	in	cells2.	Mass	spectrometry	is	the	technique	most	commonly	 used	 to	 identify	 new	 phosphosites,	whereas	 xMAP	 or	 flow	 cytometry	are	 often	 used	 to	 evaluate	 the	 phosphorylation	 of	 larger	 numbers	 of	 kinases	 in	vitro	or	ex	vivo3.		In	MS,	the	immune	system	is	chronically	activated	leading	to	specific	damage	of	the	CNS4,	5.	GWAS	studies	suggest	that	the	genetic	susceptibility	to	suffer	MS	is	mainly	due	 to	 polymorphisms	 in	 genes	 associated	 with	 the	 immune	 system,	 consistent	with	 an	 autoimmune	 pathogenesis6.	 In	 addition,	 also	 lifestyle/environmental	factors	are	likely	to	act	through	effects	on	the	adaptive	arm	of	immunity,	in	view	of	their	potent	 interactions	with	HLA	class	 II	 and	 I	 genes,	which	are	 the	 restriction	elements	 for	 CD4+	 and	 CD8+	 T	 cells,	 respectively7.	 Several	 pathways	 in	 the	immune	 system	 have	 been	 implicated	 with	 MS	 pathogenesis,	 including	 those	driven	by	the	TCR,	IL2,	IL7,	TNFa	or	NFkB	1,	8,	9,	yet	we	still	 lack	a	comprehensive	understanding	of	how	immune	pathways	are	truly	involved	in	MS.	Immunomodulatory	 drugs	 significantly	 affect	 signaling	 in	 their	 target	 cells	 after	receptor	 or	 target	 engagement.	 For	 this	 reason,	 changes	 in	 the	 phosphoprotein	network	may	represent	a	sensitive	read-out	of	drug	activity	and	of	the	response	of	immune	cells	to	the	drug3.	Generating	better	information	as	to	how	MS	alters	cell	signaling	will	benefit	the	development	of	new	therapies	to	combat	this	disease.	In	this	study	we	assessed	the	phosphorylation	of	key	kinases	and	other	proteins	in	signaling	 pathways	 associated	 with	 MS1.	 Phosphorylation	 was	 assessed	 by	performing	xMAP	assays	in	vitro	on	PBMCs	isolated	from	a	crossectional	cohort	of	MS	patients	and	healthy	controls	(HCs)	following	perturbation	with	several	stimuli	and	drugs.	Moreover,	we	genotyped	112	single	nucleotide	polymorphisms	(SNPs)	associated	with	MS6	 in	order	 to	 evaluate	 the	 influence	of	 genetic	background	on	
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the	 phosphorylation	 in	 these	 pathways.	 Immune	 cell	 subtype	 was	 also	characterized	in	a	subgroup	of	patients	by	flow	cytometry.	
Results	
Phosphoproteomic	signatures	in	MS	patients	In	 order	 to	 search	 for	 signaling	 pathways	 in	 the	 immune	 system	 that	 are	differentially	 activated	 in	 patients	with	MS,	 we	 analyzed	 the	 phosphorylation	 of	kinases	 in	PBMCs	 from	MS	patients	 and	 sex	and	age-matched	HCs.	We	 studied	a	cross-sectional	cohort	of	195	MS	patients	and	60	HCs	(see	clinical	characteristics	in	Table	 S1)	 recruited	 in	 the	 CombiMS	 project.	We	 obtained	 phosphoproteomic	information	 that	 conformed	 the	 quality	 control	 (QC)	 assessment	 from	 169	individuals	 (132	MS	 patients	 and	 37	HCs)	 and	 genotyping	 data	 from	 154	 out	 of	those	 169	 individuals	 (122	 MS	 patients	 and	 32	 HC;	 14	 subjects	 were	 excluded	because	genotyping	did	not	pass	QC	checks).	The	final	cohort	was	representative	of	the	recruited	cohort	and	between	sites	(see	SI	Appendix,	Table	S1).	The	phosphoproteomic	assays	were	designed	to	study	signaling	deregulation	using	dynamic	network	modeling.	This	linked	study	compiled	and	presented	a	manually	curated	immune-	and	MS-based	signaling	network10.	After	topological	analysis,	we	screened	the	70	antibodies	 for	 the	xMAP	assays	 that	maximized	coverage	of	 that	network,	 identifying	30	antibodies	with	good	signal	 to	noise	ratio.	We	selected	a	set	of	17	assays	that	were	suitable	for	the	multiplex	assays.	The	17	assays	used	in	the	 vitro	 assays	 were:	 AKT1,	 CREB1,	 FAK1,	 GSK3A,	 HSPB1,	 IKBA,	 JUN,	 MK03,	MK12,	MP2K1,	PTPN11,	STAT5,	STAT1,	STAT3,	STAT6,	TF65	and	WNK1	(Figure	1	and	Table	 S2).	 Considering	 that	 phosphorylation	 is	 a	 dynamic	 event	 that	 takes	place	soon	after	stimulation	and	that	is	sensitive	to	different	stimuli,	we	performed	ex	 vivo	 assays	 in	 PBMCs	 stimulated	with	 19	 different	 stimuli	 known	 to	 activate	such	 kinases	 or	 that	 are	 relevant	 for	 MS	 pathogenesis	 or	 therapy,	 including	cytokines,	metabolites	and	drugs	(see	Figure	1	and	Table	S3).	In	order	to	capture	the	 differences	 already	 present	 at	 baseline	 and	 those	 that	 require	 activation	 of	specific	pathways,	phosphorylation	was	analyzed	at	baseline	(unstimulated),	and	5	and	 25	 min	 after	 stimulation	 (stimulated).	 These	 time	 points	 after	 stimulation	were	chosen	as	they	showed	the	strongest	phosphorylation	(either	5	or	25	min),	as	
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well	 as	 the	 stimulus	 that	 produced	 the	 most	 significant	 differences	 (See	 SI	
Appendix,	 Figure	 S1).	We	checked	that	no	center	or	batch	effect	was	present	 in	the	 normalized	 phosphorylation	 levels	 by	 performing	 principal	 component	analysis.	 In	 addition,	 we	 genotyped	 our	 cohort	 for	 112	 SNPs6	 associated	 with	susceptibility	 for	MS	 (Table	 S4)	 and	 these	 genotypes	were	 used	 to	 evaluate	 the	effect	 of	 such	 SNPs	 on	 phosphorylation	 levels	 (see	 SI	 Appendix	 file	 S1	 for	 raw	genotyping	data).	First,	 we	 analyzed	 the	 baseline	 differences	 in	 phosphoproteins	 between	 MS	patients	and	HCs.	We	found	a	significant	increase	in	the	baseline	phosphorylation	of	 MP2K1	 in	 MS	 patients	 compared	 to	 controls	 after	 adjustment	 for	 multiple	comparisons	 (FDR).	 MP2K1	 is	 an	 element	 of	 the	 MAPK	 signaling	 pathway	 that	promotes	 cell	 survival	 and	 inhibits	 apoptosis,	 in	 particular	 through	 the	 NFkB	cascade.	 Indeed,	 this	 difference	 remained	 significant	 in	 the	 relapsing-remitting	(RRMS)	subgroup	after	adjusting	for	multiple	comparisons	(Wilcoxon	test	RRMS	vs	control	 p-value=0.0016,	 FDR=0.03;	 Wilcoxon	 test	 all	 MS	 patients	 vs	 control	 p-value=0.0034,	 FDR=0.065:	 Figure	 2).	 MKO3,	 GSK3A,	 JUN	 and	 STAT3	phosphorylation	levels	at	baseline	were	also	different	between	MS	and	controls	in	the	 unadjusted	 analysis,	 although	 such	 differences	 were	 not	 significant	 after	correction	 for	 multiple	 testing	 (Table	 S5).	 In	 addition,	 we	 found	 differences	 in	kinase	phosphorylation	levels	when	the	cells	were	subjected	to	distinct	stimuli	in	vitro,	 although	 these	 effects	 were	 not	 significant	 after	 adjusting	 for	 multiple	comparisons.		Then,	we	analyzed	how	the	MS	susceptibility	genotype	influenced	phosphorylation	levels	(Figure	3	and	S2).	After	FDR	correction	we	found	a	significant	influence	of	the	 TT	 genotype	 of	 the	 rs666930	 SNP	 (located	 in	 the	 phosphoglycerate	dehydrogenase	gene	-PHGDH)	on	baseline	MKO3	and	MAP2K1	phosphorylation	in	MS	 patients.	 Similarly,	 the	 CT	 genotype	 of	 the	 rs35929052	 SNP	 (located	 on	Interferon	regulatory	factor	8	-IRF8	gene,	a	key	target	of	vitamin	D	receptor11,	12)	had	 a	 significant	 influence	 on	 MAP2K1	 phosphorylation	 after	 stimulation	 with	vitamin	 D3	 (Table	 1).	 We	 found	 significant	 effects	 of	 several	 SNPs	 on	 the	phosphorylation	differences	between	MS	and	HCs	(ANOVA	adjusted	p-value<0.05).	12	 kinases	 were	 shown	 to	 be	 involved	 in	 these	 effects,	 including	 AKT1,	 FAK1,	
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GSK3A,	 JUN,	MKO3,	MP2K1,	 STAT1,	 STAT3,	 STAT5,	 STAT6,	 TF65,	WNK1	 (Table	
S6),	 although	 only	 those	 ones	 described	 above	 for	MKO3	 and	MP2K1	 (Table	 1)	remained	significant	for	the	allele-specific	pairwise	comparisons.		Indeed,	 we	 assessed	 whether	 disease	 subtype	 was	 associated	 with	 differential	phosphorylation,	 comparing	 RRMS	 and	 progressive	MS	with	 HCs.	We	 found	 the	same	 differential	 phosphorylation	 at	 baseline	 for	 MAP2K1	 in	 RRMS	 patients	relative	 to	 HCs	 but	 not	 in	 PMS	 (Figure	 2).	 Regarding	 the	 analysis	 of	phosphorylation	 levels	 and	 its	 association	 with	 MS	 associated	 SNPs	 for	 disease	subtypes,	 we	 found	 significant	 differences	 in	 JUN	 phosphorylation	 after	 insulin	stimulation	 in	 RRMS	 individuals	with	 the	 GG	 genotype	 for	 the	 rs11554159	 SNP,	located	in	the	Interferon	gamma-inducible	protein	30	(IFI-30)	gene.	Similarly,	the	effect	of	 the	CT	genotype	of	 the	rs35929052	SNP	on	the	phosphorylation	MP2K1	following	VitD3	stimulation	was	significantly	different	between	RRMS	patients	and	HCs	(Table	1).		Finally,	 we	 assessed	 the	 biological	 relationship	 of	 the	 found	 genetic	 and	phosphoprotein	 associations	 by	 performing	 a	 protein	 network	 analysis	 (see	 SI	Appendix	methods).	This	pathway	analysis	indicates	that	the	potential	influence	of	the	SNP	rs35929052	located	in	the	IRF8	gene	on	MAP2K1	kinase	activity	could	be	mediated	 by	 the	 interaction	 of	 IRF-8	 with	 TRAF6	 and	 with	 changes	 in	 the	transcription	of	EGR1	and	PPAR-gamma.	Moreover,	the	analysis	also	indicates	that	the	 influence	 of	 SNP	 rs666930	 located	 in	 the	 PHGDH	 gene	 on	 MAPK3	 can	 be	explained	by	a	physical	 interaction	between	PHGDH	protein	with	both	EGFR	and	MAP3K3	proteins	(Figure	4).	
Phosphoproteomic	signatures	associated	with	immunomodulatory	therapies	In	 order	 to	 assess	 the	 effects	 of	DMDs	 approved	 for	 the	 treatment	 of	MS	 on	 the	signaling	 network	 in	 immune	 cells	 from	 patients	 with	 MS,	 we	 analyzed	 the	phosphoproteomic	profile	of	the	17	kinases	in	patients	treated	for	more	than	one	year	with	a	given	DMD	and	compared	 it	 to	 that	 in	untreated	RRMS	patients	 (see	
Table	 S1	 for	 clinical	 details).	We	 performed	 the	 analysis	 for	 the	most	 common	disease	 modifying	 drugs	 (DMDs)	 at	 the	 time	 of	 the	 analysis,	 namely	 fingolimod	(FTY),	natalizumab	(NTZ),	 interferon	beta1a	s.q.	44	mcg	(IFNB1a)	and	glatiramer	
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acetate	 (GA).	 Teriflunomide	 and	 dimethyl-fumarate	 were	 not	 included	 in	 the	analysis	because	there	were	insufficient	patient	numbers	treated	with	these	DMDs	at	our	centers	by	the	timing	of	recruitment.	Regarding	the	changes	in	phosphorylation	induced	by	FTY,	the	phosphorylation	of	STAT1,	 MKO3	 and	 PTPN11	 after	 stimulation	 differed	 in	 FTY-treated	 patients	(n=13)	 compared	 to	 untreated	 RRMS	 patients	 (n=58:	 Table	 S7).	 Moreover,	 we	found	 significant	 differences	 between	 FTY-treated	 and	 untreated	 RRMS	 patients	after	 adjustment	 for	 genotype,	 specifically	 in	 terms	 of	 IKBA	 phosphorylation	 for	the	 AG	 rs11581062	 SNP,	 TF65	 phosphorylation	 for	 the	 GG	 rs2293152	 SNP,	 and	CREB1	phosphorylation	for	the	CT	rs6498184	SNP	(Table	S7B	and	Figure	3B).	In	summary,	in	FTY-treated	patients	we	identified	several	kinases	downstream	of	the	S1P	receptor	that	are	implicated	in	the	MAPK	or	NFKB	pathway	(e.g.	MKO3,	IKBA,	TF65)	 as	 well	 as	 several	 kinases	 that	 do	 not	 participate	 in	 the	 S1P	 receptor	pathway,	yet	that	were	related	to	pathways	involved	in	the	immune	response	(e.g.	STAT1,	STAT3,	STAT5,	STAT6).	Patients	 treated	with	NTZ	(n=19)	showed	differential	phosphorylation	of	STAT3,	STAT5,	 STAT6	 and	MP2K1	 compared	 to	 untreated	 RRMS	 patients	 (n=58:	Table	
S8).	 After	 adjusting	 for	 the	 genotype,	 we	 found	 an	 association	 with	 JUN,	 AKT1,	FAK1,	 GSK3A,	 HSPB1,	 PTN11,	 STAT1	 phosphorylation	 and	NTZ	 therapy	 (Figure	
3B).	 The	 VLA4	 (ITGA4)	 receptor	 interacts	 with	 the	 Ras/MAPK,	 PI3K	 and	 NFKB	pathways,	 and	 our	 results	 implicate	 the	 activation	 of	 several	 members	 of	 the	Ras/MAPK	 (MP2K1,	 HSPB1)	 as	 well	 as	 other	 kinases	 associated	 with	 overall	immune	activation	(STAT3,	STAT5,	STAT6).		Patients	 treated	 with	 IFNB1a	 (n=23)	 showed	 distinct	 STAT1	 phosphorylation	compared	 to	 untreated	 RRMS	 patients	 (n=58),	 with	 a	 dependence	 on	 the	 AC	rs759648	 SNP	 (adjusted	 p-value=0.0088).	 After	 adjusting	 for	 genetic	susceptibility,	 we	 observed	 an	 association	 between	 IFNB	 therapy	 and	 the	phosphorylation	of	JUN,	AKT1,	FAK1,	GSK3A,	MKO3,	MP2K1,	STAT1,	STAT3,	STAT5	and	TF65	(Figure	3B).	Considering	that	JAK/STAT	participate	in	type	1	interferon	receptor	pathways,	our	 findings	 suggest	 that	 several	kinases	 in	 this	pathway	are	
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likely	to	be	activated	(STAT1,	STAT3,	STAT5),	as	well	as	those	in	other	pathways	like	PI3K,	MAPK	or	NFKB,	supporting	the	pleiotropic	 immunomodulatory	activity	of	IFNB.	Finally,	 the	 phosphorylation	 of	 STAT6	 in	 response	 to	 insulin	 differed	 in	 patients	treated	 with	 GA	 (n=10)	 compared	 to	 untreated	 RRMS	 patients	 (n=58:	 pSTAT6	levels	 in	 GA	 treated	 patients	 0.206585;	 untreated	 patients	 0.011394;	 adjusted	 p	value=	 0.009).	 The	 JUN,	 CREB1,	 FAK1,	 GSK3A,	 STAT1,	 STAT5	 phosphoproteins	were	 more	 evident	 in	 GA-treated	 patients	 after	 adjustment	 for	 SNPs	 of	 MS	susceptibility	(Figure	3B).	Although	GA	seems	to	primarily	mediate	the	induction	of	 GA-specific	 regulatory	 T	 cells,	 it	 also	 appears	 to	 display	 broad	immunomodulatory	effects13.	Thus,	 the	activation	of	such	kinases	may	be	related	with	the	immunomodulatory	effects	of	such	cells.		
Analysis	of	kinase	phosphorylation	in	immune	cell	subtypes	by	flow	cytometry	In	 order	 to	 analyze	 the	 cell	 subtypes	 responsible	 for	 the	 differences	 in	phosphorylation,	 we	 analyzed	 the	 phosphoproteins	 levels	 in	 PBMCs	 by	 flow	cytometry.	Phosphorylation	was	assessed	 in	a	 representative	 subgroup	of	47	MS	patients	 and	 22	 HCs	 from	 the	 original	 cohort	 (Table	 S1).	 We	 analyzed	 the	phosphorylation	 of	 7	 out	 of	 the	 17	 kinases	 used	 for	 the	 xMAP	 assays	 for	which	cytometry	 assays	 passed	 QC	 and	 showed	 a	 good	 signal	 to	 noise	 ratio:	 CREB1,	HSPB1,	 IKBA,	 MK03,	 MK12,	 STAT1,	 STAT3,	 STAT5,	 TF65	 and	WNK1	 (Table	 S9	shows	 the	 list	 of	 antibodies	 used	 and	Table	S10	 show	 the	 list	 of	 ex	 vivo	 assays	conducted	 on	 each	 disease	 subgroup).	 However,	MP2K1	was	 not	 studied	 in	 this	cytometry	 substudy	due	 to	 the	 lack	of	 antibodies	 that	passed	 the	QC	 checks	 and	provide	 good	 signal	 to	 noise	 ratio.	 We	 found	 significant	 differences	 in	 the	phosphorylation	of	HSPB1	in	monocytes	(CD33+	cells)	and	STAT3	in	B	cells	(CD19+	cells)	 from	 MS	 patients	 relative	 to	 HCs.	 Moreover,	 there	 were	 significant	differences	 in	 the	 phosphorylation	 of	 STAT1,	 STAT3	 and	 TF65	 in	 CD19+	 cells	 in	PPMS	patients	compared	 to	 the	HCs.	 In	 terms	of	 the	differential	phosphorylation	related	to	the	use	of	DMDs,	we	found	significant	differential	expression	of	HSPB1	in	CD19+	cells	in	patients	treated	with	FTY	(Table	S11).	
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Discussion	We	have	performed	a	comprehensive	analysis	of	the	phosphoproteomic	changes	in	immune	 cells	 from	 patients	 with	 MS.	 We	 found	 distinct	 patterns	 of	 kinase	phosphorylation	in	patients	with	MS,	mainly	involving	the	MAPK	pathway	but	also	affecting	the	NFkB	and	STAT	pathways.	Such	pathways	are	known	to	be	critical	for	cell	 survival	 and	 proliferation,	 cell	 adhesion	 and	 chemotaxis,	 and	 the	 pro-inflammatory	 response	 of	 the	 immune	 cells.	 The	 phosphoproteomic	 data	 was	generated	 to	 perform	 logic	 network	 modeling10.	 With	 this	 approach,	 pro-inflammatory	 and	pro-survival	 pathways	were	 found	 to	be	deregulated.	 Further,	these	pathways	were	used	 for	 combination	 therapy	prediction	and	 subsequently	validated.	Hence,	both	studies	jointly	demonstrate	that	such	differential	activation	can	potentially	benefit	 from	new	 immunomodulatory	 therapies	 for	MS	and	other	autoimmune	diseases	using	approved	and	novel	kinase	inhibitors.	Our	studies	highlight	 the	prominent	 role	of	 the	MAPK	pathway	 in	 the	peripheral	immune	 system	 of	 patients	 with	 MS,	 primarily	 the	 ERK	 sub-pathway.	 This	importance	 of	 the	 MAPK	 pathway	 is	 illustrated	 not	 only	 by	 the	 increased	phosphorylation	of	MP2K1	 and	 its	 downstream	 target	MK03	but	 also,	 by	 that	 of	the	p38	sub-pathway,	as	reflected	by	HSPB1	phosphorylation.	MP2K1	(also	known	as	CFC3,	MEK1,	MKK1,	MAPKK1	or	PRKMK1)	promotes	cell	 survival	and	 inhibits	apoptosis,	in	particular	through	the	NFkB	cascade14.	MAP2K1	is	activated	through	KRAS	 and	 BRAF	 activity	 (e.g.	 after	 EGFR	 activation),	 and	 it	 phosphorylates	 ERK	kinases	and	interacts	with	the	C-Raf,	phosphatidylethanolamine	binding	protein	1,	MAP2K1IP1,	 GRB10,	 MAPK3,	 MAPK8IP3,	 MAPK1MP1	 and	 MAP3K1.	 MK03	 (also	known	as	ERK1,	MAPK3	or	PRKM3)	is	phosphorylated	by	MAP2K1,	contributing	to	the	 pro-survival	 signaling	 in	 this	 pathway.	 MK03	 is	 important	 to	 induce	 T	 cell	anergy	 and	 it	 acts	 as	 a	 negative	 regulator	 of	 dendritic	 cells,	 controlling	 their	capacity	to	prime	T	cells	towards	an	inflammatory	phenotype15.	HSPB1	(Hsp27)	is	a	small	heat	shock	protein	that	displays	chaperone	activity,	inhibits	apoptosis,	and	regulates	cell	development	and	differentiation16.	HSPB1	 is	also	part	of	 the	MAPK	pathway,	 as	 it	 is	 activated	 by	 the	 p38	 kinase	 MK2-3	 (although	 it	 can	 also	 be	activated	 by	 MK5,	 PRAK,	 PKCγ	 and	 PKD)	 and	 plays	 an	 important	 role	 in	inflammation16.	Moreover,	HSPB1	is	overexpressed	by	astrocytes	in	MS	plaques17,	
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probably	 in	 response	 to	 the	 inflammatory	 stress	 that	 helps	 protect	 the	 CNS	 and	prevent	apoptosis18.	Due	 to	 the	key	 involvement	of	 the	MAPK	pathway	 in	cancer	(RAS,	BRAF,	CRAF,	MEK1	or	MEK2	mutations),	MEK1	inhibitors	like	trametinib	or	cobimetinib	 have	 been	 approved	 for	 the	 treatment	 of	 BRAF-mutated	melanoma	and	 new	 ERK1	 inhibitors	 are	 being	 actively	 sought19.	 Therefore,	 there	 is	 an	opportunity	 to	 test	 approved	MEK1	 inhibitors,	 or	 new	ones	 under	 development,	for	their	capacity	to	modulate	the	immune	response	in	MS	and	other	autoimmune	diseases14.	MS	 genetic	 susceptibility	 also	 seems	 to	 be	 associated	 with	 signal	 pathway	activation	 as	 we	 found	 several	 SNPs	 associated	 with	 altered	 kinase	phosphorylation	 in	 immune	 cells.	 At	 present	we	 lack	 sufficient	 understanding	 of	how	 genetic	 polymorphisms	 regulate	 protein	 phosphorylation	 in	 a	 direct	 or	indirect	manner,	although	it	is	well	known	that	mutations	in	specific	kinases	alter	their	 activity	 and	 the	phosphorylation	of	 their	downstream	 targets20.	 Convincing	data	has	appeared	with	regard	to	the	TYK2	gene	polymorphism	where	a	protective	variant	 reduces	 cytokine	 signaling,	 without	 compromising	 the	 defense	 against	infections21.	Up	to	10%	of	the	human	genome	encodes	for	proteins	that	modulate	phosphorylation	 or	 other	 types	 of	 post-translational	 protein	 modifications.	Mutations	 in	 ligands,	 receptors	 and	 adaptors	 affect	 protein	 phosphorylation	indirectly,	 thereby	 suppressing	 or	 enhancing	 the	 activation	 of	 signaling	networks20.	Indeed,	recent	GWAS	studies	have	shown	association	signals	between	SNPs	at	loci	linked	to	genes	encoding	kinases	and	related	proteins,	and	numerous	complex	and	common	disease	phenotypes22,	 including	 the	association	of	SNPs	of	TyK2,	RPS6KB1,	MAPK1,	MAPK3,	RELA,	NFKB1,	STAT3	or	STAT4	with	MS6,	8,	21,	23-26.	 These	 polymorphisms	may	 be	 implicated	 in	 the	 direct	 regulation	 of	 signaling	pathways	or	they	may	serve	as	markers	of	regulatory	elements	that	segregate	with	MS.	We	here	provide	preliminary	evidences	suggesting	that	MS	risk	gene	SNPs	may	be	associated	functionally	to	kinase	signaling.		The	selection	of	SNPs	used	in	this	study	was	based	on	the	GWAS	studies	of	20136,	but	more	recent	available	studies	have	increased	the	number	of	SNPs.	In	addition,	fine-mapping	 the	 SNPs	 associated	 with	 phosphoprotein	 levels	 would	 help	 to	characterize	 the	 biological	 basis	 of	 the	 statistical	 association	 identified	 here.	 For	
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this	reason,	new	studies	with	high	genetic	coverage	would	be	required	to	further	characterize	 the	 influence	 of	 genetic	 susceptibility	 in	 the	 signaling	 pathways	involved	in	MS	pathogenesis9.		The	 effects	 recorded	 preferentially	 on	 B	 cells	 are	 of	 great	 interest,	 since	 the	depletion	 of	 CD20+	 cells	 has	 demonstrated	 unexpected	 high	 efficacy	 in	 MS27.	Several	mechanisms	 for	 the	effect	of	B	cells	have	been	presented,	 like	 the	B	cells	capacity	 to	 present	 antigens,	 their	 cytokine	 production,	 and	 development	 into	antibody	producing	cells28.	We	here	suggest	one	more	potential	piece	of	evidence	in	the	puzzle;	a	preferential	activation	of	kinases	in	B	cells.	We	 identified	altered	phosphorylation	of	 several	kinases	downstream	of	 the	S1P	receptor	that	are	involved	in	the	MAPK	or	NFKB	pathways	in	patients	treated	with	FTY.	Similarly,	we	found	alterations	in	the	phosphorylation	of	proteins	in	the	VLA4	receptor	 pathways	 in	 patients	 treated	 with	 NTZ,	 such	 as	 Ras/MAPK,	 or	 the	activation	 of	 several	 STATs	 that	 participate	 in	 type	 I	 interferon	 pathways.	Nevertheless,	 we	 also	 observed	 altered	 phosphorylation	 in	 other	 pathways.	Considering	 the	 main	 mechanism	 of	 action	 of	 some	 drugs	 (FTY	 and	 NTZ)	 is	preventing	 cell	 migration,	 it	 remain	 unclear	 to	 which	 extent	 our	 findings	 are	 a	direct	consequence	of	 the	activation	of	drug	 targeted	pathways	or	a	 reflection	of	the	immune	system	adaptation	to	changes	in	immune	cells	dynamics.	However,	the	crossectional	 design	 of	 our	 study	 and	 the	 influence	 of	 such	 drugs	 in	 PBMCs	composition	prevents	to	establish	a	definite	causality	between	drug	use	and	kinase	activation,	 and	 for	 this	 reason	 prospective	 validation	 studies	 are	 required	 to	confirm	such	 findings.	 Indeed,	 longitudinal	 studies	are	also	 required	 for	defining	the	role	of	these	kinases	in	the	response	to	therapy.	Anyway,	phosphoproteomics	is	evolving	as	 the	method	of	choice	 in	some	areas	of	 the	drug	discovery	process,	and	 it	 is	 has	 also	 become	 more	 suitable	 for	 the	 discovery	 of	 novel	 targets	 or	biomarkers3.		This	 study	 has	 several	 limitations,	 such	 as	 the	 use	 of	 a	 medium	 through-put	approach	such	as	xMAP,	or	flow	cytometry	with	limited	number	of	assays	available	with	 a	 good	 signal	 to	 noise	 ratio.	 Indeed,	 we	 have	 measured	 only	 levels	 of	phosphorylated	 proteins,	 without	 solving	 whether	 this	 was	 due	 to	 increased	phosphorylation	 or	 by	 higher	 abundance	 of	 the	 kinase	 or	 both.	 However,	 the	
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kinases	 we	 have	 included	 in	 the	 analysis	 are	 known	 to	 participate	 in	 pathways	previously	 associated	 with	 MS	 and	 autoimmunity,	 supporting	 the	 biological	relevance	of	our	results1.	The	selection	of	 the	stimuli	was	based	 in	 the	 literature	pointing	 for	 T	 cell	 activation	 and	 for	 this	 reason	 specific	 activators	 of	 B	 cell	response	 were	 not	 included.	 Our	 analysis	 simplified	 signaling	 process	 to	 the	analysis	 of	 phosphorylation	 events	 but	 not	 other	 post-translational	 changes,	employing	 few	 time-points	 and	 conditions.	 Moreover,	 our	 study	 was	 cross-sectional,	 whereas,	 longitudinal	 analysis	 will	 be	 required	 in	 order	 to	 define	 the	response	to	each	of	the	DMDs	at	the	clinical	level	and	being	used	for	identifying	the	role	of	 several	pathways	and	kinases	 in	 the	 response	 to	 therapy.	 In	addition,	we	performed	many	statistical	tests	and	obtained	results	adjusted	for	statistical	multi-testing	across	the	entire	study,	although	this	approach	does	not	allow	us	to	exclude	false	positive	results.	Indeed,	the	use	of	multiple	testing	corrections	decreases	the	power	of	 the	study	 for	detecting	 true	associations	and,	 for	example,	only	MP2K1	remained	significant	 in	 the	comparison	between	patients	and	controls.	However,	despite	such	 limitations,	our	study	provides	evidence	of	 the	specific	activation	of	the	MAPK	pathway	 in	 the	 immune	 cells	 of	MS	 patients,	which	may	 promote	 the	development	of	MAPK	targeted	therapies	for	MS.	
Methods	See	SI	Appendix,	Supplementary	Text	for	extended	method	explanations.			
Subjects	We	recruited	255	subjects,	195	patients	with	MS	and	60	healthy	controls	matched	for	 age	 and	 sex	 with	 the	 RRMS	 group,	 from	 4	 MS	 centers	 (Table	 S1):	 Hospital	Clinic	 of	 Barcelona	 (n=69);	 Karolinska	 Institute	 (n=64);	 University	 of	 Zurich	(n=40)	 and	 Charité	 University	 (n=82).	 Patients	 fulfilled	 the	 McDonald	 2005	criteria29	 and	 their	 disease	 subtype	was	 defined	 using	 Lublin	 criteria30.	 Patients	were	allowed	 to	 receive	any	 therapy	and	 in	 the	previous	6	months	 they	had	not	required	any	adjustment	to	their	therapy.		
xMAP	assays	
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xMAP	 assays	 were	 performed	 blinded	 at	 ProtAtOnce	 (Athens,	 Greece).	 We	optimized	the	assays	from	a	list	of	70	candidates	based	in	QC	checks	and	the	signal	to	 noise	 analysis	 and	obtained	 a	 final	 list	 of	 17	phosphoproteins	with	 optimized	assays	(Table	S2).	We	used	a	set	of	19	stimuli	that	included	pro-inflammatory	and	pro-oxidant	 stimuli;	 immunomodulatory	 stimuli;	 neuroprotectants	 and	 anti-oxidants;	 and	 DMDs	 (Table	 S3).	 Such	 stimuli	 are	 known	 to	 activate	 several	pathways	 known	 being	 associated	 with	 MS	 pathogenesis	 (e.g.	 MAPK,	 NfKB	 or	STAT)	 or	 trigger	 the	 activation	 of	 DMDs	 receptors	 (Fig.	 1).	 The	 samples	 were	collected	at	the	baseline	(time	0),	and	5	and	25	min	after	stimulation.	All	the	data	was	 normalized	 after	 reading	 the	 signals.	 Changes	 in	 phosphorylation	 for	 each	protein	and	each	patient	were	calculated	with	respect	to	the	control	conditions31.	The	phosphorylation	of	each	protein	in	response	to	stimulation	was	defined	as	the	log2	of	the	response	to	the	stimulus	relative	to	the	response	to	the	medium.	
Cytometry	Patient’s	samples	were	washed	three	times	and	stained	with	the	antibodies	(Table	
S6).	 Four	 subtypes	 of	 immune	 cells	 were	 identified	 and	 gated:	 CD4+	 cells;	 CD8+	cells;	B	cells	(CD19);	and	monocytes	(CD33).		
Genotyping	Genotyping	was	performed	on	DNA	samples	collected	from	the	subjects,	assessing	SNPs	previously	validated	as	associated	with	MS6.	The	final	list	includes	112	SNPs,	including	1	SNP	associated	with	HLA-DRB1*1501	(Table	S4).		
Statistical	and	bioinformatic	Analysis	We	compared	pairs	of	groups	using	a	Wilcoxon	test	(for	baseline)	or	a	T-test	(for	responses	 to	 stimuli)	 using	 R	 software.	 Genotype	 to	 phosphoprotein	 levels	associations	 were	 tested	 using	 two-way	 ANOVA,	 and	 with	 each	 SNP	 as	 a	 first	independent	 factor	and	 the	patient	group	as	a	 second	 factor.	The	 false	discovery	rate	was	always	corrected	using	the	Benjamini-Hochberg	procedure	(reported	as	significant	when	FDR	<0.05).	Protein	network	analysis	is	described	in	SI	Appendix,	Supplementary	Text.	
Ethics	statement	
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This	 investigation	 has	 been	 conducted	 according	 to	 Declaration	 of	 Helsinki	principles.	The	study	was	approved	by	the	Ethics	Committee	of	the	Hospital	Clinic	of	 Barcelona,	 Hospital	 San	 Martino	 of	 Genova,	 Charité	 University	 of	 Berlin	 and	University	of	Oslo.	Patients	were	recruited	by	neurologists	after	they	had	provided	their	signed	informed	consent	prior	to	inclusion	in	the	study.		
Data	and	materials	availability:	The	phosphoproteomic	dataset	can	be	found	at	https://github.com/saezlab/combiMS,	 together	 with	 the	 code	 allowing	 network	modeling	of	signaling	pathways10.	
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Figure	Legends	
Figure	1.	 The	 immune	 signaling	network	 in	MS.	The	figure	shows	the	stimuli	used	 for	 the	 in	vitro	assays	 (purple	hexagons	on	 the	 left),	 targeting	receptors	on	the	cell	membrane	(orange	circles),	although	some	stimuli	directly	target	kinases	or	pathways	(e.g.	H2O2	directly	induces	oxidative	stress).	Membrane	receptors	are	linked	 to	 intracellular	 kinases	 (light	 brown	 circles)	 as	 part	 of	 their	 intracellular	signaling	networks.	The	specific	phosphoproteins	tested	in	these	assays	are	shown	as	 red	 circles	 associated	 to	 the	master	 kinase.	 Finally,	 kinases	 influence	 cellular	and	molecular	processes.	Stimulation	(e.g.	phosphorylation)	is	indicated	by	green	arrows	whereas	inhibitory	interactions	(e.g.	dephosphorylation)	is	 indicated	by	a	red	T	link.	
Figure	2.	MP2K1	phosphorylation	 in	PBMCs	 from	MS	patients	and	controls.	Phosphorylation	of	MP2K1	 in	PBMCs	 from	MS	patients	and	controls,	 as	assessed	by	xMAP	and	compared	with	a	Wilcoxon	test:	*	p<0.05;	**	adjusted	p<0.05.	
Figure	3.	The	phosphoproteomic	signature	in	MS.	The	lines	in	the	circle	graph	show	 the	 pairs	 of	 stimuli/phosphoproteins	 found	 to	 be	 significant	 and	 the	corresponding	MS	susceptibility	genes	(ANOVA	test	for	association	between	kinase	levels	and	SNPs,	Benjamini	correction	for	multiple	testing).	The	outer	circle	shows	the	17	phosphoproteins	 analyzed	and	 the	19	 stimuli	 used,	while	 the	 inner	 circle	shows	 the	112	SNPs	 tested	 (color	coded	 for	 the	mean	allelic	distribution)	where	the	SNP	indicated	by	the	link	is	referred	to	by	its	letter	code.	a)	Phosphoproteomic	signature	 in	 MS,	 healthy	 controls,	 and	 the	 RMS	 and	 PMS	 subtypes	 of	 MS.	 b)	Phosphoproteomic	signature	of	the	DMDs	compared	to	untreated	RRMS	patients.	
Figure	4.	Protein	network	analysis	of	phosphoproteins	and	SNPs	associated	
with	MS.	The	graph	shows	the	proteins	from	either	genes	containing	MS-susceptibility	SNPs	(in	red)	or	phosphokinases	(in	blue)	found	associated	in	our	analysis.	a)	first-order	physically	interactions	of	the	studied	proteins	identified	on	the	iRefIndex	and	MetaBase/MetaCore	database.	b)	transcriptional	regulation	(dashed	lines)	and	physical	interactions	(solid	lines)	of	the	associated	proteins	
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identified	using	the	TieDie	algorithm	on	the	background	of	directed	MetaBase	network.	
Table 1. Differential phosphorylation in PBMCs from MS patients relative to healthy 
controls. The table shows the kinases that were more strongly phosphorylated in MS patients 
relative to the HCs, indicating the stimulus used in the in vitro assays and the susceptibility 
SNPs (Benjamin correction for multiple tests). The results are shown as the mean ± SD. 
Unstimulated basal phosphoprotein levels were compared using a Wilcoxon test, whereas a 
phosphorylation after stimulation was normalized and compared using a T-test. 
 Stimulus SNP: allele phosphorylation levels p Adjusted p 
MS   MS HCs   
MKO3 baseline rs666930: TT 937 ± 480 463 ± 86 0.0011 0.004 
MP2K1 
vitD3 rs35929052: CT 0.44 ± 0.42 -0.24 ± 0.2 1.32E-05 0.0016 
baseline rs666930: TT 3849 ± 1794 2041 ± 646 0.0019 0.04 
RRMS       
JUN INS rs11554159: GG 0.12 ± 0.14 -0.017 ± 0.1 0.00022 0.027 
MP2K1 vitD3 rs35929052: CT 0.48 ± 0.47 -0.24 ± 0.2 6.71E-05 0.008 
VitD3, vitamin D3; INS, insulin 	
Figure	1.	The	immune	signaling	network	in	MS.	The	figure	shows	the	stimuli	used	for	the	in	vitro	
assays	(purple	hexagons	on	the	left),	targeting	receptors	on	the	cell	membrane	(orange	circles),	
although	some	stimuli	directly	target	kinases	or	pathways	(e.g.	H2O2	directly	induces	oxidative	
stress).	Membrane	receptors	are	linked	to	intracellular	kinases	(light	brown	circles)	as	part	of	their	
intracellular	signaling	networks.	The	specific	phosphoproteins	tested	in	these	assays	are	shown	as	
red	circles	associated	to	the	master	kinase.	Finally,	kinases	influence	cellular	and	molecular	
processes.	Stimulation	(e.g.	phosphorylation)	is	indicated	by	green	arrows	whereas	inhibitory	
interactions	(e.g.	dephosphorylation)	is	indicated	by	a	red	T	link.	
Figure	2.	MP2K1	phosphorylation	in	PBMCs	from	MS	patients	and	controls.	Phosphorylation	of	
MP2K1	in	PBMCs	from	MS	patients	and	controls,	as	assessed	by	xMAP	and	compared	with	a	Wilcoxon	
test:	*	p<0.05;	**	adjusted	p<0.05.	
a	
b	
Figure	3.	The	phosphoproteomic	signature	in	MS.	The	lines	in	the	circle	graph	show	the	pairs	of	stimuli/
phosphoproteins	found	to	be	significant	and	the	corresponding	MS	susceptibility	genes	(ANOVA	test	for	
association	between	kinase	levels	and	SNPs,	Benjamini	correction	for	multiple	testing).	The	outer	circle	
shows	the	17	phosphoproteins	analyzed	and	the	19	stimuli	used,	while	the	inner	circle	shows	the	112	
SNPs	tested	(color	coded	for	the	mean	allelic	distribution)	where	the	SNP	indicated	by	the	link	is	
referred	to	by	its	letter	code.	a)	Phosphoproteomic	signature	in	MS,	healthy	controls,	and	the	RMS	and	
PMS	subtypes	of	MS.	b)	Phosphoproteomic	signature	of	the	DMDs	compared	to	untreated	RRMS	
patients.	
Figure	4.	Protein	network	analysis	of	phosphoproteins	and	SNPs	associated	with	MS.	The	graph	
shows	the	proteins	from	either	genes	containing	MS-susceptibility	SNPs	(in	red)	or	
phosphokinases	(in	blue)	found	associated	in	our	analysis.	a)	first-order	physically	interactions	of	
the	studied	proteins	identified	on	the	iRefIndex	and	MetaBase/MetaCore	database.	b)	
transcriptional	regulation	(dashed	lines)	and	physical	interactions	(solid	lines)	of	the	associated	
proteins	identified	using	the	TieDie	algorithm	on	the	background	of	directed	MetaBase	network.	
Supplementary	figure	S1.	Phosphoprotein	levels	in	healthy	controls	and	in	patients	with	MS.	
Heat	map	of	the	raw	phosphorylation	levels	(after	normalization)	annotated	for	different	
disease	subtypes	and	treatments.	Imputation	of	the	missing	values	using	knn:	k=10	for	each	
cpp	10	nearest	patients/samples.	
Supplementary	figure	S2.	Allelic	distribution	of	MS	susceptibility	SNPs	in	MS	patients	and	controls,	and	their	
association	with	the	phosphoprotein	levels.	For	each	SNP	we	show	6	sub-sectors:	3	for	each	allele	variant	for	the	two	
groups	(MS	and	HC).	The	heat	map	shows	the	level	of	one	of	the	17	phosphoproteins	in	response	to	the	19	different	
stimuli	for	each	radius.	Each	sector	related	to	a	given	SNP	at	a	specific	radius	could	be	considered	as	a	separate	heat	map	
of	the	phosphorylation	response	of	the	selected	kinase	stratified	by	genetic	variance	at	the	position	of	this	SNP.	Circular	
tracks	from	out	to	in:	1)	SNP	name;	2)	allele	status	of	the	SNP:	reference	homozygous	(grey),	heterozygous	(orange),	
alternative	homozygous	(red);	3)	disease	status,	MS	(blue)	or	HC	(yellow);	4)	the	combination	of	allele	status	and	disease	
status	defines	the	number	of	rows	in	the	heat	map	for	each	specific	phosphoprotein;	5)	heat	maps	of	the	response	of	the	
specific	phosphoproteins	as	a	function	of	the	overall	variance	in	the	data	(from	out	to	in):	MKO3,	STAT1,	MP2K1,	STAT3,	
PTN11,	TF65,	HSPB1,	MK12,	AKT1,	FAK1,	WNK1,	STAT5,	GSK3A,	JUN,	IKBA,	STAT6,	CREB1.	Each	phosphoprotein	heat	map	
has	4-6	rows	(number	of	allele	statuses	*	number	of	disease	statuses)	and	20	columns,	related	to	the	stimuli:	anti-CD3,	
BDNF,	ConA,	DMF,	EGCG,	FTY,	H2O2,	IFNG,	IL1A,	IL6,	INS,	LPS,	NaCl,	PolyIC,	IFNb1a,	S1P1,	Teriflunomide,	TNFA,	vitD3.	The	
color	represents	the	phosphorylation	response	(log2	[phosphorylation	of	the	selected	kinase	after	stimulation/
phosphorylation	of	the	selected	kinase	in	the	medium]).	Heat	map:	blue	-	lower	values,	red	-	higher	values	averaged	over	
the	cohort	with	the	specific	allele/disease	status.	
